AbbVie Biotech Ventures

Investor type Corporate Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 40
Average round size
The average size of a deal this fund participated in
Portfolio companies 30
Rounds per year 5.00
Lead investments 3
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 6
Key employees 8

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Pharmaceutical
  • Medical

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of AbbVie Biotech Ventures:
Typical Co-investors
AbbVie Biotech Ventures is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after AbbVie Biotech Ventures:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Nitrome Biosciences

Health Care
$7M02 Nov 2021 Jackson, Mississippi, United States

Quanta Therapeutics

Health Care
Medical Device
$60M26 Oct 2021 San Francisco, California, United States


Health Care
$50M18 Aug 2021 Boston, Massachusetts, United States

Starday Foods

Food and Beverage
$4M17 Aug 2021 -

Stemson Therapeutics

$15M15 Jul 2021 San Diego, California, United States

Carisma Therapeutics

Health Care
Life Science
$47M07 Jan 2021 Philadelphia, Pennsylvania, United States

Faze Medicines

$81M10 Dec 2020 Cambridge, Massachusetts, United States

Palleon Pharmaceuticals

Health Care
$100M17 Sep 2020 Massachusetts, United States


Health Care
Life Science
$33M28 Jul 2020 Milan, Lombardy, Italy
Jnana Therapeutics Closes $50 Million Series B Financing to Advance Lead PKU Program and Small Molecule Pipeline Based on Next Gen Chemoproteomic Platform

– Jnana Therapeutics, a biotechnology company utilizing its next generation chemoproteomic platform to target SLC transporters and other well-validated but hard-to-drug targets, announced the closing of a $50m Series B financing.
– The financing was led by RA Capital Management, and included all existing investors, including Polaris Partners, Versant Ventures, Avalon Ventures, AbbVie Ventures and Pfizer Ventures.
– Proceeds from this financing will enable Jnana to progress its lead program for the treatment of phenylketonuria (PKU) into clinical development, while advancing a pipeline of additional programs and continuing to invest in its innovative and validated RAPID platform for the discovery of small molecule therapeutics for hard-to-drug targets.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent AbbVie Biotech Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: